Merck Announces That V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults

KENILWORTH, N.J.--(BUSINESS WIRE) June 22, 2020 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from two initial Phase 3 studies evaluating the safety,

Latest News Clinical News 49
Read All

Myovant Sciences Announces Priority Review and FDA Acceptance of New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer

BASEL, Switzerland, June 22, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that its New Drug Applicatio

Latest News Clinical News 49
Read All

FDA Approves Lupkynis (voclosporin) for Adult Patients with Active Lupus Nephritis

VICTORIA, British Columbia & ROCKVILLE, Md.-- January 22, 2021 -- Aurinia Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Lupkynis (voclosporin)

Latest News NDA News 55
Read All

Glenmark Becomes the First Pharmaceutical Company in India to Receive Regulatory Approval for Oral Antiviral Favipiravir for the Treatment of Mild to Moderate COVID-19

MUMBAI, India, June 20, 2020 /PRNewswire/ -- In a landmark development for COVID-19 patients in India, Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announc

Latest News Clinical News 52
Read All

NIH Halts Clinical Trial of Hydroxychloroquine

June 20, 2020 -- A clinical trial to evaluate the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalized with coronavirus disease 2019 (COVID-19) has been stopped by t

Latest News Clinical News 50
Read All

FDA Approves Cabenuva (cabotegravir and rilpivirine) Long-Acting Injectable HIV Treatment and Vocabria (cabotegravir) Oral HIV Treatment

London, 21 January 2021 -- ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that

Latest News NDA News 62
Read All

GSK COVID-19 Vaccine Development Collaboration with Clover Biopharmaceuticals Begins Clinical Trials

London, UK June 19, 2020 -- GSK’s scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover today announced the init

Latest News Clinical News 49
Read All

GSK Announces FDA Advisory Committee Meeting to Review Belantamab Mafodotin for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

London UK - 19 June 2020 -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) will convene a meeting of the Oncologic Drugs Advisory Committee (ODAC) to rev

Latest News Clinical News 50
Read All

Clover Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate

Perth, AUSTRALIA and Chengdu, CHINA – 19 June 2020 -- Clover Biopharmaceuticals today announced that the first participants have been dosed in the Phase 1 first-in-human study evaluating the company’s

Latest News Clinical News 61
Read All

Ridgeback Biotherapeutics Announces Launch of Phase 2 Trials Testing EIDD-2801 as Potential Treatment for COVID-19

MIAMI--(BUSINESS WIRE)--June 19, 2020 -- Ridgeback Biotherapeutics announces the launch of two Phase 2 clinical trials to test the efficacy of EIDD-2801 as an anti-viral treatment for COVID-19. Phase

Latest News Clinical News 44
Read All

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following Giroctocogene Fitelparvovec (SB-525) Gene Therapy

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE) June 18, 2020 -- Pfizer Inc. (NYSE:PFE)andSangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data

Latest News Clinical News 60
Read All

Chi-Med Announces Fruquintinib Granted U.S. FDA Fast Track Designation for Metastatic Colorectal Cancer

London: Thursday, June 18, 2020 -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation

Latest News Clinical News 50
Read All
News
- CLINIEXPERT -
Int'l Clinical Service Expert

We are the leader
Because of our professionism